The monoclonal antibody G250 (mAbG250) raised against a human renal cell carcinoma (RCC) has been shown to react with a large number of RCCs. Recently, G250 antigen was isolated and found to be homologous to the MN/CA9 gene originally identified in HeLa cells. To determine whether G250 antigen (MN/CA IX/G250) could be a potential therapeutic target and a tumour marker, a total of 147 cases of RCC were investigated immunohistochemically as well as by reverse transcriptase polymerase chain reaction (RT-PCR) analysis. In addition, total RNAs extracted from patients' peripheral blood samples were analysed for MN/CA9/G250 mRNA signals. Immunohistochemistry demonstrated strong expression in 128/147 (87.1%) of RCCs, in contrast to the lack of expression observed in normal tissues. RT-PCR analyses of frozen specimens resulted in the clear detection of MN/CA9/G250 mRNA signals in 137/147 (93.2%), and despite subtle differences the results were almost identical to those for immunohistochemistry. Although high-grade and -stage tumours exhibited significantly lower expression than low-grade and -stage tumours, a large proportion of tumours expressed MN/G250 protein as well as mRNA. RT-PCR analysis of patients' blood samples revealed the presence of circulating MN/CA9/G250 expressing cells. These findings suggest that this antigen may be a potential therapeutic target as well as diagnostic marker for RCCs.
extremely difficult. It is well known that RCC displays a unique biological profile (Ritchie et al, 1987) , e.g. long dormancy of metastases and spontaneous regression of metastatic disease, suggesting that RCC patients can raise abortive immune responses against as yet unknown tumour components. Investigations of RCC patient's immune status have also indicated that this influences the biological behaviour of the tumour . Since RCC is relatively resistant to conventional treatment, such as radiation and chemotherapy, immunotherapy seems to be the most promising therapeutic approach. Although biological response modifiers have shown a substantial efficacy in selected cases, the response rates hardly exceed 30% and most patients cannot be cured (Wirth, 1993) . Clearly, tumour-specific immunotherapy would be advantageous but unequivocal evidence for the existence of unique tumour-specific antigens in human malignancies is still lacking. A murine monoclonal antibody G250 (mAbG250) raised against human RCC is, however, known to react with a large proportion of RCCs, whereas the reactivity with normal tissues is restricted to cells of gastric mucosa and large bile ducts (Oosterwijk et al, 1986) . Taking advantage of the specific reactivity with RCC, we have shown that treatment of mice bearing RCC xenografts with mAbG250 results in significant anti-tumour effects (Van Dijk et al, 1995) . We also have shown that vaccination with the internal image anti-idiotype antibodies against mAbG250 results in the destruction of established RCC tumours, suggesting potential benefit with surrogate antigens for active specific immunotherapy (Uemura et al, 1994a (Uemura et al, , 1994b . Clinical trials with 131 I-mAbG250 as well as 131 I-chimeric mAbG250 (ch-mAbG250) for radiodiagnosis have shown safety and tumour specificity (Oosterwijk et al, 1993; Steffens et al, 1997) . These results suggest that this antigen can be useful as a therapeutic and diagnostic target.
Recently, the G250 antigen was sequenced and was revealed by database analysis to be homologous to the MN/CA IX antigen, a tumour-associated antigen originally identified in HeLa cells Oosterwijk et al, 1996) . This antigen (MN/CA IX/G250) is a plasma membrane glycoprotein with an apparent molecular weight of 54/58 kDa, detectable in several types of malignancies; e.g. cervical and ovarian cancer (Liao et al, 1996) , renal cancer (Oosterwijk et al, 1986) , colorectal cancer (Saarnio et al, 1998) , oesophageal cancer (Turner et al, 1997) , bladder cancer (Uemura et al, 1996) , but not in the normal tissues except alimentary tract, suggesting a possible role in oncogenesis. Sequential analysis has demonstrated that this gene (MN/ CA9/G250) is a novel member of the carbonic anhydrase (CA) family and MN/CA IX/G250 is considered to be the only tumourassociated CA isoenzyme. Although the functional significance of MN/CA IX/G250 in oncogenesis remains unclear, MN/CA IX/G250 can induce malignant phenotype in murine NIH 3T3 fibroblasts, suggesting that MN/CA IX/G250 plays a role in control of cell proliferation and transformation . In addition, recent reports confirmed that MN/CA IX/G250 may be useful as a potentially important biomarker for cervical carcinomas Brewer et al, 1996) and RCC (Liao et al, 1997; McKiernan et al, 1997) . However, MN/CA IX/G250 MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas has also been detected in normal tissues in the alimentary tract . A sequential study of stomach cDNA showed no difference between normal and tumour tissue-derived cDNAs, indicating that MN/CA9/G250-associated oncogenesis may depend on the gene expression without mutations . Moreover, a recent investigation by Ivanov et al (1998) focused on the genes involved in von Hippel-Lindau (VHL)-mediated carcinogenesis, and indicated down-regulation of MN/CA9/G250 gene expression in RCC cell lines by wild-type VHL transgenes (Ivanov et al, 1998) .
Thus, MN/CA9/G250 gene may be related to carcinogenesis in RCC and MN/CA IX/G250 antigen may be a tumour-associated biomaker in RCC. Although the G250 antigen has been cloned and found to be homologous to MN/CA9, a precise correlation between MN/CA9 gene and G250 antigen expression has not been shown. Therefore, we evaluated MN/G250 expression in a large number of RCC extensively by both immunohistochemistry and RT-PCR assay, and correlated the data with clinicopathological parameters. Moreover, since the haematogenous metastasis of RCC is well established and there is no reliable serological marker as a prognostic indicator, we applied RT-PCR technology for molecular detection of circulating MN/CA9/G250-positive cells in blood samples from RCC patients.
MATERIALS AND METHODS

Cells
Human RCC SK-RC series cell lines, reactive and non-reactive with mAbG250, were obtained from the Sloan-Kettering Institute, New York. YCR-1 was kindly supplied by Professor T Shuin of the Department of Urology, Kochi Medical College. Cells were cultured in RPMI-1640 medium supplemented with L-glutamine and 10% fetal bovine serum.
Specimens
RCC and corresponding normal kidney tissues were obtained by radical operations in our department. All specimens were certainly kept under RNAase-free conditions immediately after nephrectomy, and small pieces of tumour or normal kidney tissue were frozen in liquid nitrogen and stored at -80°C. The remainder of each kidney was submitted for pathological examination by the central pathologist (KI) at this institute.
Monoclonal antibody
A murine monoclonal antibody, mAbG250 (IgG1, IgG2a), which recognizes the MN/CA IX/G250 antigen, was used for immunohistochemical staining and mixed haemadsorption assays (MHA). The isolation and characterization of mAbG250 has been described elsewhere (Oosterwijk et al, 1986) .
Immunohistochemistry of RCC specimens
Immunohistochemistry of frozen tissues was carried out as described previously (Uemura et al, 1995) . Briefly, 4-5-micronthick cryostat sections were airdried for 1 h and fixed in acetone/methanol for 10 min at room temperature. After washing in phosphate-buffered saline (PBS), tissue sections were incubated with mAbG250 for 1 h at room temperature. After a three further washes with PBS, the tissue sections were incubated with goat anti-mouse IgG conjugated to horseradish peroxidase, preincubated with 10% normal human serum. The tissue sections were developed with 3-3′-diaminobenzidine and 0.01% hydrogen peroxide for 10 min at room temperature. After washing with tap water, the slides were counterstained with haematoxylin, and mounted with Permount.
Mixed haemadsorption assay
RCC cell lines were examined for MN/CA IX/G250 antigen expression on the cell surface by MHA. Briefly, the cells cultured in 60-well plates overnight were incubated with appropriately diluted mAbG250 for 60 min at room temperature, and subsequently with indicator sheep red blood cells (SRBC) treated with mouse anti-SRBC and goat anti-mouse IgG antibody for 60 min at room temperature. The reaction was determined as positive when over 25% of the target cells formed rosettes.
RT-PCR analysis
Peripheral blood lymphocytes separated by centrifugation using Ficoll-Conray (IBL, Gunma, Japan), tissues and cell lines were used for preparation of total RNAs by homogenization in guanidium thiocyanate and centrifugation through caesium chloride. Total RNAs were reverse transcribed with SuperScript RNAase H reverse transcriptase (Gibco-BRL), using random primers. The resulting cDNA fragments were then amplified by PCR, using combined sense and anti-sense degenerate primers (sense primer; 5′-ACTGCTGCTTCTGATGCCTGT-3′, 126-146 nt, anti-sense; 5′-AGTTCTGGGAGCGGCGGGA-3′, 620-602 nt). The amplification was achieved with 30 cycles, each consisting of denaturation (95°C, 2 min), annealing (68°C 2 min), and extension (72°C, 1 min). The PCR products from several tissue RNAs were 495 bp in length. For blood samples, to obtain a higher sensitivity of the RT-PCR assay, PCR Southern blots were carried out. Briefly, PCR products were electrophoresed in 1.5% agarose gels and transferred to nitrocellulose filters. The cDNA probe (167-447 nt) was hybridized with filters at 42°C in the presence of 40% formamide, and the filters were finally washed with 0.2 × standard saline citrate, 0.1% sodium dodecyl sulphate at 60°C. The size of the DNA was determined by comparison with lambda phage DNA fragments digested with HindIII. 
RT-PCR assay sensitivity for detection of circulating MN/CA9/G250-positive cells
To determine the sensitivity of the RT-PCR assay for detection of circulating MN/CA9/G250-expressing cells, SKRC-44 (MN/ CA9/G250-positive cell line) cells were serially diluted into 10 ml whole blood obtained from a 36-year-old healthy male volunteer (MN/CA9/G250-negative blood). Briefly, a single cell suspension of SKRC-44 was prepared in PBS and serial dilutions were carried out. Different dilutions were added to 10-ml aliquots of normal blood samples, to give concentrations of 0, 10 0 , 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 cells per 1 ml whole blood. For lymphocyte separation, the blood samples were centrifuged using Ficoll-Conray. Total RNA was extracted from the cell pellets and RT-PCR analysis was performed as described above.
Statistical analysis
Correlations between MN/CA IX/G250 expression and clinicopathological parameters were evaluated using the χ 2 test. A probability < 0.05 was considered significant.
RESULTS
MN/G250 expression in RCC specimens
mAbG250 stained 128 of 147 (87.1%) cases, most demonstrating homogeneous and strong binding. The staining strength and percentages of positive tumour cells correlated in different areas of the same RCC, in accordance with the results of our previous study. Data for relations between MN/CA IX/G250 expression and tumour stage and grade are summarized in Table 1 . Significant inverse links were noted in both cases P < 0.005 and P < 0.0001 respectively, i.e. high-grade tumours expressed MN/CA IX/G250 antigen at a significantly lower rate (33.3%) than low-grade tumours (98.6%). MN/CA IX/G250 expression of tumour cells was not related to the morphological type of RCC (Tables 2 and 3 (Table 4 ). All MHA-positive cell lines (SKRC-6, 10, 38, 44, 52) expressed MN/CA9 mRNA, but not vice versa.
Detection of circulating MN/CA9/G250-positive cells in the blood
RT-PCR sensitivity assay revealed that one single MN/CA9/G250-positive cell in 1 ml whole blood was detectable (Figure 3) . Standard RT-PCR analysis (30 cycles) revealed the presence of circulating MN/CA9/G250-positive cells in several blood samples taken from inferior vena cava or renal vein during radical nephrectomies, but not in peripheral blood samples (data not shown). To obtain high sensitivity for detecting MN/CA9/G250-positive circulating cells, nested PCR as well as PCR Southern blotting analyses were carried out (Figure 4) . Thereby, 76.2% (32/42) of blood samples from RCC patients demonstrated MN/CA9/G250 mRNA, although this was also the case for 32.2% (10/31) of the blood samples from healthy donors without any disease (Table 5 and Figure 4 ). The presence of MN/CA9/G250-expressing cells in control blood was confirmed by the sequence analysis (data not shown).
DISCUSSION
RCC is relatively resistant to conventional anticancer treatment such as radiation, chemotherapy or hormonal therapy, and radical operations are considered the only way to achieve cures. However, it also has a unique biological profile, demonstrating long dormancy of metastasis and spontaneous regression after nephrectomy, and an investigation concerning immune status of patients with RCCs revealed that the biological behaviour of tumours was influenced by host factors (Ritchie et al, 1987) . So far, immunotherapy seems to be the most promising treatment approach and cytokine immunotherapy for RCC, e.g. with interferons and interleukin-2, has worldwide 6, 10, 12, 14, 17, 29, 33, 38, 39, 42, 44, 45, 52, 59, become the most common first therapeutic alternative next to nephrectomy. Nevertheless, the prognosis of RCC patients with disseminated disease is still extremely poor, and a more specific therapeutic approach is needed. We have focused on the G250 antigen expressed on a large proportion of RCCs as a promising target molecule. Isolation and sequential analysis revealed G250 to be identical to MN/CA IX (Oosterwijk et al, 1996) , a N-glycosylated protein originally identified in HeLa cells by mAb M75 (Pastoreková et al, 1992) and distributed on the plasma membrane as well as in the nucleus. Immunohistochemical studies with mAb M75 as well as mAbG250 for MN/CA IX/G250 expression have been carried out in several malignancies. In RCC, the first immunohistochemical study of MN/CA IX/G250 was reported by Oosterwijk et al (1986) using mAbG250. However, it was not considered that both mAb M75 and mAbG250 recognized the same antigen MN/CA IX/G250. Another report by Liao et al (1997) using mAb M75 demonstrated very similar results, i.e. 45 of 47 primary RCC (95%) were MN/CA IX/G250-positive, all clear cell tumours with or without granular/spindle cell expressing MN/CA IX/G250. Our extensive study with mAbG250 revealed an inverse correlation between MN/CA IX/G250 expression and tumour stage and grade, as described in other diseases (Brewer et al, 1996; Turner et al, 1997; Saarnio et al, 1998) . Brewer et al (1996) have shown that low expression of MN/CA IX/G250 correlates with poor prognostic factors, e.g. poorly differentiated tumour, lymph node metastasis, depth of cervical stromal invasion, suggesting low MN/CA IX/G250 expression in tumour cells with higher malignant potential. Similar results have been reported in colorectal cancer (Saarnio et al, 1998 ) and oesophageal cancer (Turner et al, 1997) . After cloning of MN/CA9 gene, this gene expression of benign human tissues and RCC was investigated by RT-PCR assay using an oligonucleotide primer specific for MN/CA9/G250 cDNA (McKiernan et al, 1997) . In this RT-PCR study of 17 RCC cases, 12 pure clear cell type tumours Figure 3 Sensitivity assay of RT-PCR and PCR Southern blot. Different dilutions of SKRC-44 (MN/CA IX/G250-positive) cell suspensions were added to 10 ml aliquots of normal whole blood. Until at concentration of one SKRC-44 cell in 1 ml whole blood, the mRNA signal can be detectable showed MN/CA9/G250 expression and no expression was observed in the remaining five granular or papillary cell type tumours with or without clear cell elements. Although the first report by Oosterwijk et al (1996) emphasized that reactivity with mAbG250 is not related to morphological appearance of the cells, the two current reports suggest that MN/CA IX/G250 may be cell-specific tumour-associated protein, i.e. a useful potential marker for clear cell type RCC. Based on our results, a majority of RCC are MN/CA IX/G250-positive; mAbG250(+)/RT-PCR(+) in 128 (87.1%), mAbG250(-)/ RT-PCR(+) in nine (6.1%) and mAbG250(-)/RT-PCR(-) in ten cases (6.8%), respectively, with RT-PCR being a most reliable detection method. It seems that MN/CA IX/G250 expression is related to the clear cell type, with alveolar or tubular structures. However, some non-clear cell type tumours with or without clear cell elements were also MN/CA IX/G250-positive. Immunohistochemical and RT-PCR analyses for these groups were consistent, so they may be indicated for immunotherapy. With the others, where the RT-PCR approach was more sensitive, diagnostic applications may still be expected. (McKiernan et al, 1997) . However, they subsequently also found MN/CA9/G250-expressing cells in normal blood samples (McKiernan et al, 1998) . This was confirmed by our RT-PCR analysis with the same primers and conditions as they employed (data not shown). Similar results have been reported for other malignancies. For example, wide ranges of antigen detection rates of circulating prostatic-specific antigen (PSA) or prostaticspecific membrane antigen (PSM) positive cells in prostate cancer cases have also been described (Hamdy et al, 1992; Sokoloff et al, 1996; Ignatoff et al, 1997) . With the RT-PCR analyses of MacKiernan and ourselves, hypersensitive RT-PCR assays with PCR Southern blots or nested RT-PCR (total 50 cycles), allowed detection of MN/CA9/G250-expressing cells in peripheral blood samples. To confirm whether circulating MN/CA9/G250-positive cells could be real RCC cells, further investigation with additional markers is required. Unfortunately, there is no reliable marker specific for RCC detection presently available. Since normal alimentary tissues express MN/CA IX/G250, further precise study with other normal tissues including haematological cells, is needed to investigate the possible significance of MN/CA IX/G250-positive cells in normal blood samples. However, because of the significantly high detection rate in RCC, quantitative analysis of MN/CA9/G250 expression might allow discrimination from non-RCC. In order to obtain both high sensitivity and specificity for detection of circulating MN/CA9/G250-positive cells, optimal settings of RT-PCR are under investigation.
Cell line RT-PCR MHA
In conclusion, our investigation of both MN/CA IX/G250 and MN/CA9/G250 gene expression in a large number of RCC specimens revealed the majority to express MN/CA IX/G250. Immunohistochemical findings with mAbG250 (128/147, 87.1%) was almost identical to the results of RT-PCR analysis (137/147, 93.2%). We also showed that RT-PCR analysis of blood samples from RCC patients can detect circulating MN/CA9/G250-positive cells, although the sensitivity (32/42, 76.2%) and specificity (21/31, 77.8%) were relatively low. Our findings suggest that the MN/CA9/G250 antigen is a promising tool as a therapeutic target and a diagnostic marker for detection of residual disease after RCC resection.
